Publications by authors named "Simone Rubant"

Claim this Profile
L
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Simone Rubant

Am J Clin Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C Luna, Simone Rubant

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman, Simone Rubant

Dermatol Ther (Heidelb)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C Luna, Simone Rubant

Dermatol Ther (Heidelb)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman, Simone Rubant

Dermatol Ther (Heidelb)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU).
Natalia Kirsten, Simone Rubant, Susana Gomis-Kleindienst, Heike Pfeiffer-Vornkahl, Matthias Augustin

J Dtsch Dermatol Ges· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.
Liisi Raam, Ilona Hartmane, Skaidra Valiukevičienė, Arfenya E Karamova, Eniko Telegdy, Simone Rubant

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu

J Dermatolog Treat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Simone Rubant

Dermatol Ther (Heidelb)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
Alan Menter, Diamant Thaçi, Kim A Papp, Jashin J Wu, Mareike Bereswill, Simone Rubant

J Am Acad Dermatol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1.
Anne Dudeck, Mandy Leist, Simone Rubant, Anja Zimmermann, Jan Dudeck

Exp Dermatol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constitutive and functionally relevant expression of JAM-C on platelets.
Luise Erpenbeck, Simone Rubant, Katja Hardt, Sentot Santoso, Wolf-Henning Boehncke

Thromb Haemost· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation.
Margarethe Müller, Kirill Essin, Kerstin Hill, Heike Beschmann, Simone Rubant

J Biol Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression.
Simone A Rubant, Ralf J Ludwig, Sandra Diehl, Katja Hardt, Roland Kaufmann

J Invest Dermatol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity.
Juliane Fritzsche, Susanne Alban, Ralf J Ludwig, Simone Rubant, Wolf-Henning Boehncke

Biochem Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo.
Simone Rubant, Ralf J Ludwig, Jeannette Pfeffer, Petra Schulze-Johann, Roland Kaufmann

Exp Dermatol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis